Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Malka

Showing results (151-160 of 192) with videos related to

Pageof 20
Sort By:
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|March 8, 2026
Targeting the liver: Insights from a tertiary center on post-operative hepatic arterial oxaliplatin for metastatic colorectal cancerKevin Sarti, Elsa El-Rawadi, Maximiliano Gelli, et al.
Journal of Medical Genetics|May 28, 2013
CDH1 germline mutations and the hereditary diffuse gastric and lobular breast cancer syndrome: a multicentre studyPatrick R Benusiglio, David Malka, Etienne Rouleau, et al.
The Oncologist|June 2, 2019
Characteristics of <i>BRAF</i><sup></sup> Mutant, Deficient Mismatch Repair/Proficient Mismatch Repair, Metastatic Colorectal Cancer: A Multicenter Series of 287 PatientsChristelle de la Fouchardière, Romain Cohen, David Malka, et al.
Journal of Medical Genetics|May 31, 2015
Hereditary diffuse gastric cancer syndrome: improved performances of the 2015 testing criteria for the identification of probands with a CDH1 germline mutationPatrick R Benusiglio, Chystelle Colas, Etienne Rouleau, et al.
Nature Medicine|April 26, 2022
Digital remote monitoring plus usual care versus usual care in patients treated with oral anticancer agents: the randomized phase 3 CAPRI trialOlivier Mir, Marie Ferrua, Aude Fourcade, et al.
International Journal of Cancer|May 3, 2020
Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studiesSarina A Piha-Paul, Do-Youn Oh, Makoto Ueno, et al.
European Journal of Cancer (Oxford, England : 1990)|July 6, 2020
Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX)Yves Rinaldi, Anne-Laure Pointet, Faiza Khemissa Akouz, et al.
Bulletin Du Cancer|June 30, 2019
[Dihydropyrimidine dehydrogenase deficiency screening for management of patients receiving a fluoropyrimidine: Results of two national practice surveys addressed to clinicians and biologists]Marie-Anne Loriot, Fadil Masskouri, Paolo Carni, et al.
European Journal of Cancer (Oxford, England : 1990)|December 22, 2023
Precision medicine for KRAS wild-type pancreatic adenocarcinomasImen Ben-Ammar, Adrien Rousseau, Rémy Nicolle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 19, 2011
Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1Jean Philippe Arnault, Christine Mateus, Bernard Escudier, et al.
Pageof 20

Showing results (151-160 of 192) with videos related to

Sort By:
Pageof 20
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|March 8, 2026
Targeting the liver: Insights from a tertiary center on post-operative hepatic arterial oxaliplatin for metastatic colorectal cancerKevin Sarti, Elsa El-Rawadi, Maximiliano Gelli, et al.
Journal of Medical Genetics|May 28, 2013
CDH1 germline mutations and the hereditary diffuse gastric and lobular breast cancer syndrome: a multicentre studyPatrick R Benusiglio, David Malka, Etienne Rouleau, et al.
The Oncologist|June 2, 2019
Characteristics of <i>BRAF</i><sup></sup> Mutant, Deficient Mismatch Repair/Proficient Mismatch Repair, Metastatic Colorectal Cancer: A Multicenter Series of 287 PatientsChristelle de la Fouchardière, Romain Cohen, David Malka, et al.
Journal of Medical Genetics|May 31, 2015
Hereditary diffuse gastric cancer syndrome: improved performances of the 2015 testing criteria for the identification of probands with a CDH1 germline mutationPatrick R Benusiglio, Chystelle Colas, Etienne Rouleau, et al.
Nature Medicine|April 26, 2022
Digital remote monitoring plus usual care versus usual care in patients treated with oral anticancer agents: the randomized phase 3 CAPRI trialOlivier Mir, Marie Ferrua, Aude Fourcade, et al.
International Journal of Cancer|May 3, 2020
Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studiesSarina A Piha-Paul, Do-Youn Oh, Makoto Ueno, et al.
European Journal of Cancer (Oxford, England : 1990)|July 6, 2020
Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX)Yves Rinaldi, Anne-Laure Pointet, Faiza Khemissa Akouz, et al.
Bulletin Du Cancer|June 30, 2019
[Dihydropyrimidine dehydrogenase deficiency screening for management of patients receiving a fluoropyrimidine: Results of two national practice surveys addressed to clinicians and biologists]Marie-Anne Loriot, Fadil Masskouri, Paolo Carni, et al.
European Journal of Cancer (Oxford, England : 1990)|December 22, 2023
Precision medicine for KRAS wild-type pancreatic adenocarcinomasImen Ben-Ammar, Adrien Rousseau, Rémy Nicolle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 19, 2011
Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1Jean Philippe Arnault, Christine Mateus, Bernard Escudier, et al.
Pageof 20